Speaker Profile

Ph.D., CSO, EVP, Intellia Therapeutics

Biography
Laura Sepp-Lorenzino, Ph.D. leads Research and Early Development at Intellia Therapeutics. Before joining Intellia, Laura was at Vertex, Alnylam, Merck and Memorial Sloan-Kettering. She received her professional degree in Biochemistry from the University of Buenos Aires, Argentina and both her M.S. and Ph.D. in Biochemistry from New York University. Laura is a member of the BOD of Taysha Gene Therapies, the Alliance for Regenerative Medicine and the Oligonucleotide Therapeutics Society, and sits on the SABs of Thermo Fisher Scientific, Zymergen, and the U.K. Nucleic Acid Therapy Accelerator.

Talk
Advances in Therapeutic CRISPR/Cas9 Genome Editing
Intellia Therapeutics is a leading clinical-stage genome editing company, developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. Highlights from our clinical programs in vivo and ex vivo will be presented, including the first demonstration of CRISPR knockout in humans.


 Session Abstract – PMWC 2022 Silicon Valley


  • Dismantling Barriers to Biomarker Testing Through Collaboration
    Session Chair: Omar Perez, AstraZeneca - Nikki Martin, LUNGevity
    - Jenn Higgins, Guardant Health
    - Kamala Maddali, Deep Lens
    - Dan Rhodes, Strata Oncology
  • Health Systems Perspective: Leveraging Real-world Evidence to Improve Patient Care
    Session Chair: Anna Berry, Syapse
    - Mary Walters, Aurora Health
    - Haythem Y Ali, Henry Ford Health System
  • Comprehensive Profiling: Combination of Tissue and Plasma Biomarker Strategies
    Session Chair: Maggie Rougier-Chapman, Personal Genome Diagnostics (PGDx)
    - Cynthia Pointer, Genapsys
    - Ravi Kolhe, Augusta University
  • Immuno-oncology Monitoring for Drug Efficacy
    Session Chair: Padma Sundar, Oncocyte
  • Reimagining Oncology - Closing the Gaps between Science and Clinic
    Session Chair: Christian Wolfrum, Siemens Healthineers
    - Ben Gonzales, Biognosys AG
    - Debanti Sengupta, Varian
    - Rangarajan Sampath, Siemens Healthineers
    - Steven Artandi, Stanford
  • Challenges to Implementing Precision Oncology in the Community Setting
    Session Chair: Jerry Mitchell, Foundation Medicine
    - Erika Brown, One Cancer Place
    - Lee Schwartzberg, OneOncology
    - Vivian Lee, Patient Advocate
  • Community Hospitals Reimbursement Landscape and Modeling
    Session Chair: Brady Davis, Canexia Health
    - Julie Eggington, CGI (Center for Genomic Interpretation)